Dihydralazine
Phase 3Small molecule
Dihydralazine is one of 7 small molecule programs targeting Myocardial fibrosis. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Myocardial Fibrosis
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Invokana
WWim Janssens
Approved
Esbriet
LLegacy Health System
Approved
Aldactone
PfizerPhase 3
Torasemide
Boehringer IngelheimApproved
Dihydralazine
UUniversity Medical Center Goettingen
Phase 3
Henagliflozin
TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dihydralazine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details